{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:46:26Z","timestamp":1787071586498,"version":"build-2736575974"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>\n                    A\n                    <jats:sc>BSTRACT<\/jats:sc>\n                  <\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Epilepsy is increasingly prevalent among older adults, with stroke, neurodegenerative diseases, and brain tumors being the most common etiologies. Treatment in this population is complicated by age-related physiological changes and the risk of polypharmacy, requiring careful selection of antiseizure medications (ASMs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A retrospective chart review was conducted for patients aged 60 years and above who were newly diagnosed with epilepsy and attended the neurology clinics at King Abdulaziz University Hospital, Jeddah, Saudi Arabia, between January 2015 and December 2020. Demographic and clinical data, including ASM prescriptions and tolerability, were analyzed using SPSS version 20 (SPSS Statistics developed by IBM for data management, Armonk, New York, United States of America).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 82 patients were included (mean age: 69 years; 58.5% male). Levetiracetam (LEV) was the most commonly prescribed ASM (69.5%), followed by phenytoin (37.8%). Valproic acid, carbamazepine, lamotrigine (LTG), and topiramate were used to a lesser extent. Prescription patterns did not significantly differ by age group or gender. LEV was favored due to its favorable safety profile and minimal drug interactions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>LEV is the most preferred ASM for elderly patients with epilepsy in Jeddah, likely due to its efficacy, tolerability, and low interaction risk. Individualized treatment strategies remain essential, given the complex comorbidities and pharmacological considerations in this age group.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jfmpc.jfmpc_452_25","type":"journal-article","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T21:00:30Z","timestamp":1759006830000},"page":"3956-3959","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Managing epilepsy in older adults: A Saudi Arabian perspective on drug selection"],"prefix":"10.4103","volume":"14","author":[{"given":"Mazen A.","family":"Basheikh","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, University of Jeddah, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"R1-20251009","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1136\/bmj.331.7528.1317","article-title":"Epilepsy in elderly people","volume":"331","author":"Brodie","year":"2005","journal-title":"BMJ"},{"key":"R2-20251009","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/S0140-6736(00)02149-8","article-title":"Epilepsy in elderly people","volume":"355","author":"Stephen","year":"2000","journal-title":"Lancet"},{"key":"R3-20251009","first-page":"1048","article-title":"Drug therapy reviews:Clinical pharmacology of antiepileptic drugs","volume":"35","author":"Browne","year":"1978","journal-title":"Am J Hosp Pharm"},{"key":"R5-20251009","doi-asserted-by":"crossref","first-page":"18024","DOI":"10.1038\/nrdp.2018.24","article-title":"Epilepsy","volume":"4","author":"Devinsky","year":"2018","journal-title":"Nat Rev Dis Prim"},{"key":"R7-20251009","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/epi.12074","article-title":"Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes","volume":"54","author":"Glauser","year":"2013","journal-title":"Epilepsia"},{"key":"R8-20251009","doi-asserted-by":"crossref","first-page":"27","DOI":"10.14581\/jer.19003","article-title":"Epilepsy in the elderly:Treatment and consideration of comorbid diseases","volume":"9","author":"Lee","year":"2019","journal-title":"J Epilepsy Res"},{"key":"R9-20251009","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.yebeh.2003.09.007","article-title":"Use of levetiracetam in a population of patients aged 65 years and older:A subset analysis of the KEEPER trial","volume":"4","author":"Ferrendelli","year":"2003","journal-title":"Epilepsy Behav"},{"key":"R10-20251009","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S1059-1311(03)00070-0","article-title":"Levetiracetam monotherapy for elderly patients with epilepsy","volume":"13","author":"Alsaadi","year":"2004","journal-title":"Seizure"},{"key":"R11-20251009","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1212\/WNL.62.5_suppl_2.S24","article-title":"Special considerations in treating the elderly patient with epilepsy","volume":"62","author":"Ramsay","year":"2004","journal-title":"Neurology"},{"key":"R12-20251009","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1053\/seiz.2000.0380","article-title":"A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy","volume":"9","author":"Betts","year":"2000","journal-title":"Seizure"},{"issue":"(Suppl 7)","key":"R13-20251009","first-page":"299","article-title":"Behavioral changes associated with levetiracetam use in patients with epilepsy","volume":"42","author":"Asconap\u00e9","year":"2001","journal-title":"Epilepsia"},{"key":"R14-20251009","first-page":"e14956","article-title":"A comparison of seizure prophylaxis:Phenytoin versus levetiracetam","volume":"13","author":"Fiani","year":"2021","journal-title":"Cureus"},{"key":"R15-20251009","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s13760-019-01132-4","article-title":"Antiepileptic drug therapy in the elderly:A clinical pharmacological review","volume":"119","author":"Kaur","year":"2019","journal-title":"Acta Neurol Belg"},{"key":"R16-20251009","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1097\/TA.0b013e3182826e84","article-title":"A prospective multicenter comparison of levetiracetam versus phenytoin for early posttraumatic seizure prophylaxis","volume":"74","author":"Inaba","year":"2013","journal-title":"J Trauma Acute Care Surg"},{"key":"R17-20251009","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s40263-021-00827-8","article-title":"The pharmacology and clinical efficacy of antiseizure medications:From bromide salts to cenobamate and beyond","volume":"35","author":"L\u00f6scher","year":"2021","journal-title":"CNS Drugs"},{"key":"R18-20251009","first-page":"465","article-title":"Valproic acid hepatic fatalities","volume":"46","author":"Bryant","year":"1996","journal-title":"III. U. S. experience since 1986. Neurology"},{"key":"R19-20251009","doi-asserted-by":"crossref","first-page":"695","DOI":"10.2165\/00023210-200216100-00004","article-title":"Pharmacological and therapeutic properties of valproate:A summary after 35 years of clinical experience","volume":"16","author":"Perucca","year":"2002","journal-title":"CNS Drugs"},{"key":"R20-20251009","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.clinbiochem.2013.06.012","article-title":"Adverse drug reactions induced by valproic acid","volume":"46","author":"Nanau","year":"2013","journal-title":"Clin Biochem"},{"key":"R21-20251009","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s12883-016-0663-7","article-title":"Comparative effectiveness of levetiracetam, valproate and carbamazepine among elderly patients with newly diagnosed epilepsy:Subgroup analysis of the randomized, unblinded KOMET study","volume":"16","author":"Pohlmann-Eden","year":"2016","journal-title":"BMC Neurol"},{"key":"R23-20251009","first-page":"476","article-title":"Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy","volume":"345","author":"Brodie","year":"1995","journal-title":"UK lamotrigine\/carbamazepine monotherapy trial group. Lancet"},{"key":"R24-20251009","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1111\/j.1528-1167.2007.01128.x","article-title":"An international multicenter randomized double-blind controlled trial of lamotrigine and sustained-release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly","volume":"48","author":"Saetre","year":"2007","journal-title":"Epilepsia"},{"key":"R25-20251009","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1212\/01.WNL.0000167384.68207.3E","article-title":"New onset geriatric epilepsy:A randomized study of gabapentin, lamotrigine, and carbamazepine","volume":"64","author":"Rowan","year":"2005","journal-title":"Neurology"},{"key":"R26-20251009","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/j.1528-1167.2008.01584.x","article-title":"Topiramate in older patients with partial-onset seizures:A pilot double-blind, dose-comparison study","volume":"49","author":"Ramsay","year":"2008","journal-title":"Epilepsia"}],"container-title":["Journal of Family Medicine and Primary Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_452_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:48:56Z","timestamp":1787068136000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_452_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_452_25","relation":{},"ISSN":["2249-4863","2278-7135"],"issn-type":[{"value":"2249-4863","type":"print"},{"value":"2278-7135","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"2025-03-18","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-28","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}